Want to see AU:TRJ full AI Analyst Report?
TRJ Stock Chart & Stats
AU$0.18
>-AU$0.01(-2.38%)
At close: 4:00 PM EDT
AU$0.18
>-AU$0.01(-2.38%)
Day’s Range― - ―
52-Week RangeAU$0.15 - AU$0.85
Previous CloseN/A
Volume203.06K
Average Volume (3M)175.63K
Market Cap
AU$38.22M
Enterprise ValueAU$75.90M
Total Cash (Recent Filing)AU$12.62M
Total Debt (Recent Filing)AU$57.95M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding152,863,630
10 Day Avg. Volume97,968
30 Day Avg. Volume175,629
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)0.31
Price to Sales (P/S)0.19
P/FCF Ratio-9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.55Price Target Upside205.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$168.53M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRecurring consumable and replacement-part sales can support repeat purchasing because they are embedded in routine laboratory testing. That model can make revenue more resilient than one-time equipment sales and provide a durable base for customer retention and ongoing cross-selling across analytical workflows.
Broad Laboratory Market ReachThe company’s presence across research, environmental, food, clinical, pharmaceutical and biotech laboratories broadens the end-market opportunity. This application range can reduce reliance on a single testing niche and gives Trajan multiple channels through which laboratory demand may support longer-term growth.
Manageable LeverageModerate leverage, with debt-to-equity near 0.59, leaves more balance-sheet flexibility than an aggressively levered structure. That relative capacity may help the company fund operations and pursue its laboratory-products strategy while it works through earnings volatility, although leverage has edged higher.
Bears Say
Unproven ProfitabilityTrajan has not yet established consistent profitability, with net losses continuing through 2025 and 2026. This limits internally generated capital for expansion, makes earnings power harder to assess, and leaves future returns dependent on a sustained improvement in operating performance.
Weakening Revenue And Margin ProfileThe recent top-line contraction and sharp gross-margin decline indicate that operating momentum has weakened rather than progressed steadily. Even with some improvement in EBIT and EBITDA margins, modest and volatile profitability makes durable earnings growth less certain over the next several quarters.
Deteriorating Cash ConversionThe sharp reversal from positive free cash flow in 2024–2025 to materially negative free cash flow in 2026 weakens the company’s ability to fund investment internally. Persistent cash-conversion volatility could increase reliance on funding or require an operating rebound to support ongoing needs.
Trajan Group Holdings Ltd News
TRJ FAQ
What was Trajan Group Holdings Ltd’s price range in the past 12 months?
Trajan Group Holdings Ltd lowest share price was AU$0.14 and its highest was AU$0.85 in the past 12 months.
What is Trajan Group Holdings Ltd’s market cap?
Trajan Group Holdings Ltd’s market cap is AU$38.22M.
When is Trajan Group Holdings Ltd’s upcoming earnings report date?
Trajan Group Holdings Ltd’s upcoming earnings report date is Mar 01, 2027 which is in 131 days.
How were Trajan Group Holdings Ltd’s earnings last quarter?
Trajan Group Holdings Ltd released its earnings results on Aug 26, 2026. The company reported AU$0.011 earnings per share for the quarter.
Is Trajan Group Holdings Ltd overvalued?
According to Wall Street analysts Trajan Group Holdings Ltd’s price is currently Undervalued.
Does Trajan Group Holdings Ltd pay dividends?
Trajan Group Holdings Ltd does not currently pay dividends.
What is Trajan Group Holdings Ltd’s EPS estimate?
Trajan Group Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trajan Group Holdings Ltd have?
Trajan Group Holdings Ltd has 152,863,630 shares outstanding.
What happened to Trajan Group Holdings Ltd’s price movement after its last earnings report?
Trajan Group Holdings Ltd reported an EPS of AU$0.011 in its last earnings report. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Trajan Group Holdings Ltd?
Currently, no hedge funds are holding shares in AU:TRJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trajan Group Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.55 (205.56% Upside)
AU$0.55 (205.56% Upside)
Blogger Sentiment
Bullish
AU:TRJ Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.60%
12-Months-Change
Fundamentals
Return on Equity
-0.62%
Trailing 12-Months
Asset Growth
-5.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Trajan Group Holdings Ltd
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.
TRJ Stock 12 Month Forecast
Average Price Target
AU$0.55
▲(205.56% Upside)
Technical Analysis
Compumedics Limited
―
Nanosonics Limited
―
Proteomics International Laboratories Ltd.
―
Genetic Signatures Ltd.
―
IDT Australia Limited
―